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Abstract: 
Manganese (Mn) is an environmental risk factor for Parkinson's disease (PD). Recessive 
inheritance of PARK2 mutations is strongly associated with early onset PD (EOPD). It is widely 
assumed that the influence of PD environmental risk factors may be enhanced by the presence of 
PD genetic risk factors in the genetic background of individuals. However, such interactions may 
be difficult to predict owing to the complexities of genetic and environmental interactions. Here 
we examine the potential of human induced pluripotent stem (iPS) cell-derived early neural 
progenitor cells (NPCs) to model differences in Mn neurotoxicity between a control subject (CA) 
with no known PD genetic risk factors and a subject (SM) with biallelic loss-of-function 
mutations in PARK2 and family history of PD but no evidence of PD by neurological exam. 
Human iPS cells were generated from primary dermal fibroblasts of both subjects. We assessed 
several outcome measures associated with Mn toxicity and PD. No difference in sensitivity to 
Mn cytotoxicity or mitochondrial fragmentation was observed between SM and CA NPCs. 
However, we found that Mn exposure was associated with significantly higher reactive oxygen 
species (ROS) generation in SM compared to CA NPCs despite significantly less intracellular 
Mn accumulation. Thus, this report offers the first example of human subject-specific differences 
in PD-relevant environmental health related phenotypes that are consistent with pathogenic 
interactions between known genetic and environmental risk factors for PD. 
Parkinson's disease | manganese | human induced pluripotent stem cells | gene–Keywords: 
environment interactions | neurotoxicology 
Article: 
1. Introduction 
Parkinson's disease (PD), the second most common neurodegenerative disorder, is clinically 
characterized by bradykinesia, resting tremor, rigidity, and loss of postural reflexes. PD etiology 
is largely unknown but there is strong evidence to implicate environmental risk factors, 
especially exposure to heavy metals and pesticides, in its pathogenesis (Elbaz and Moisan, 2010, 
Schapira, 2011 and Tanner et al., 2011). Exposure to Mn is an important environmental risk 
factor for PD (Aschner and Erikson, 2009, Bowman et al., 2011 and Guilarte, 2010). Exposure to 
very high concentrations of Mn causes manganism, a syndrome that shares many features with 
PD (Guilarte, 2010, Lucchini et al., 2009, Olanow, 2004 and Racette et al., 2011). High levels of 
Mn in the ambient air has been associated with earlier age of onset for PD, indicating that Mn 
may accelerate the process of age-related neuronal loss (Finkelstein and Jerrett, 2007). 
Manganism most frequently occurs from occupational Mn exposure such as may occur in 
mining, welding metals, and dry battery manufacturing (Keen et al., 2000). However, a more 
insidious course due to a cumulative exposure to small doses over a long period of time is also 
possible (Lucchini et al., 2009). A prospective study assessing the long term neurotoxic effects 
of Mn exposure in bridge construction workers has concluded that while cognitive decline 
improved in previous workers after 3.5 years follow up, motor and mood disturbances 
precipitated by Mn exposure were persistent despite decreasing blood Mn levels (Bowler et al., 
2011). Moreover, it has been shown that Mn exposure causes up regulation of α-synuclein 
(SCNA) and down regulation of Tyrosine hydroxylase (TH) and Parkin (PARK2) in 
dopaminergic neurons, resulting in increased oxidative stress and eventual cell death (Wang et 
al., 2009). 
The mechanisms by which Mn exerts its neurotoxic effects are not well understood. Some of the 
proposed mechanisms include disruption of mitochondrial metabolism (Zhang et al., 2008) and 
oxidative stress (Zhang et al., 2004). The influence of Mn exposure on individuals is determined 
by a combination of variables including age and nutritional status (Aschner and Erikson, 2009). 
Nonetheless, the neurotoxic effects of Mn tend to vary greatly between individuals (Roth, 2006). 
This variation is most likely due to genetic variability that renders an individual more or less 
sensitive to the toxic effects of Mn which eventually manifests in variable clinical course (Roth, 
2006). For example, the cytotoxic effect of Mn is dependent on its intracellular levels (Yin et al., 
2010) and genetic variations like polymorphisms and copy number variations involving key 
components of Mn transport such as DMT1 (He et al., 2011) and the iron/Mn exporter 
ferroportin (Yin et al., 2010) can alter Mn sensitivity. Thus genetic variation between 
individuals, which cannot be readily quantified or studied, using established model systems, 
complicates assessment of personalized risk to Mn exposure. 
 
Genetic susceptibility plays a significant role in the pathogenesis of PD. One study indicated a 
concordance rate for nigrostriatal dysfunction at 45% in monozygotic twins where one twin has a 
PD diagnosis (Burn et al., 1992). The concordance rate of subclinical dopaminergic dysfunction 
might be even higher (75%) in monozygotic twins as assessed by positron emission tomography 
(Piccini et al., 1999). Of importance, for a subset of PD patients the disease can be directly 
linked to inheritance of a monogenic risk factor (Gasser, 2009 and Lesage and Brice, 2009). Loss 
of function mutations in PARK2, which encodes the E3 ubiquitin ligase Parkin, is the most 
common cause of autosomal recessive PD (Kitada et al., 1998). Loss of Parkin is associated with 
mitochondrial dysfunction and cytotoxicity suggesting a neuroprotective role involving 
maintenance of mitochondrial integrity ( Narendra et al., 2008 and Narendra et al., 2009). 
Further highlighting its role in neuroprotection, PARK2 over expression was shown to rescue 
dopaminergic neurons from cell death caused by Mn toxicity (Higashi et al., 2004). 
 
Manganism and familial cases of PD represent the opposite ends of the environmental versus 
genetic etiology of parkinsonian pathologies. However, complex interactions between 
environmental and genetic risk factors likely underlie the majority of idiopathic PD cases. These 
genetic risk factors may include susceptibility genes that increase PD risk but may not directly 
cause disease (Vance et al., 2010). Furthermore, even in the presence of a strong PD genetic risk 
factor, like biallelic inheritance of PARK2 loss-of-function mutations, there is a wide variation in 
age-of-onset with documented cases of asymptomatic individuals many decades older than 
family members with inheritance of the same monoallelic genetic risk factor ( Marder et al., 
2010 and von Coelln et al., 2004). A particularly relevant example is a 56-year old patient with 
no evidence of Parkinsonism despite inheritance of compound heterozygous mutations in 
PARK2 (Deng et al., 2006). Remarkably, four siblings of this patient who inherited the identical 
mutations in maternal and paternal alleles were diagnosed with EOPD (age of onset ranging from 
30 to 38 years old). Thus, even under conditions of the relatively minimal genetic variation of a 
single family, other genetic and/or environmental factors play a critical role in the pathogenesis 
of PD. 
 
Here we tested the hypothesis that two human subjects with distinct genetic risk profiles for PD 
would display differences in the vulnerability of NPCs to Mn exposure, a major PD 
environmental risk factor. The two subjects are identified here as “CA”, a male healthy control 
with no family history of PD; and “SM”, a male subject with compound heterozygous loss-of-
function mutations in PARK2 and a family history of EOPD in his full sibling with the same 
PARK2 genotype. Despite the family history and the genetic background, SM, age 43, has no 
evidence of PD on neurological exam. The approach we took to test our hypothesis utilized iPS 
cell technology to make subject-specific NPCs via a dual-SMAD inhibition differentiation ( 
Chambers et al., 2009, Hao et al., 2010, Neely et al., 2012 and Takahashi et al., 2007). Human 
iPS derived cells retain the unique genetic characteristics of each research subject, thus offering 
the possibility of modeling personalized environmental risk to Mn toxicity (Kumar et al., 2012). 
We assessed Mn neurotoxicity in SM and CA derived NPCs focusing on the PD-relevant 
outcome measures of cell death, mitochondrial fragmentation, oxidative stress and cellular Mn 
accumulation. We report patient-specific differences in Mn accumulation and reactive oxygen 
species generation. This report provides proof of principle for detecting gene–environment 
interactions between human subjects and a neurotoxicant using an iPS cell-based model system. 
 
2. Materials and methods 
2.1. iPS cells generation, validation, and maintenance 
We derived the lines used in our work from two subjects through either viral- or episomal-
mediated reprogramming as described previously (Okita et al., 2011 and Takahashi et al., 2007). 
Punch skin biopsies were used to obtain primary epidermal fibroblasts from subjects CA and SM 
under Vanderbilt IRB#080369 (KE). The first two letters of every line designates the de-
identified human subject, while the numeral following designates each independent iPS line. 
Lines generated through viral transduction include CA4, CA6, SM3, SM4, SM5, and lines 
generated through the non-integrating episomal method include CA11, SM14. The PARK2 
mutation in SM fibroblasts, first identified by clinical genetic tests, was confirmed through 
sequencing of cDNA to be a 40 bp deletion in exon 3 of one allele and a complete deletion of 
exons 5 and 6 on the other allele (manuscript submitted). All lines were validated for the 
expression of pluripotency markers by immunocytochemistry and quantitative reverse-
transcriptase (QRT-PCR). Chromosomal euploidy was confirmed by karyotyping for all lines by 
Genetic Associates Inc. (Nashville, TN). Additional information on the generation, validation, 
and maintenance of the iPS lines is described in detail elsewhere (Neely et al., 2012). 
 
2.2. Neural induction and splitting of NPCs 
NPCs were generated by adapting a dual-SMAD inhibition protocol developed by Lorenz Studer 
(Sloan-Kettering Institute, NY) and colleagues (Chambers et al., 2009) substituting the Bone 
Morphogenetic Protein (BMP) inhibitor DMH1 for Noggin (Neely et al., 2012). Our method of 
NPCs differentiation is described in detail elsewhere (Neely et al., 2012). These early neuronal 
precursors express PAX6, a marker of human neural ectoderm, as well as FOXG1, OTX2 and 
SOX1 and are thought to be the first stage in neuronal lineage commitment (Zhang et al., 2010). 
In brief, neural induction begins on what is designated as day 1 when the neuralization medium 
(Knockout DMEM/F12, 15% KSR, Glutamax (all from Invitrogen), penicillin/streptomycin 
(Mediatech), nonessential amino acids, and 55 μM β-mercaptoethanol (both from Sigma)) 
containing 10 μM SB431542 (Tocris) and 0.5 μM DMH1 (gift from Dr. Charles Hong, 
Vanderbilt University) is added to the iPS cells approximately four days after their initial plating 
on Matrigel-coated wells (BD Biosciences, San Jose, CA; Fig. 1). Neuralization continues for 7 
days, which coincides with high expression of PAX6, the main NPC marker used in this study 
(Neely et al., 2012). Most of the experiments include splitting of NPCs on day 6 of neuralization 
to either control for the cell count (in cell survival and ROS experiments) or to enable clear 
visualization of mitochondrial morphology in mitochondrial fragmentation analysis studies. 
 
Fig. 1. Experimental design. iPS cells were plated for each experiment on Matrigel-covered 12 
well or 96 well plates at a density of 6 × 104 cell/ml. On the fourth day after plating they reach a 
confluency of approximately 90% and that is when neuralization starts (day 1) with the dual-
SMAD inhibition protocol. On day 7 of neuralization 80–90% of the cell population in culture 
are NPCs (PAX6+). We exposed the cells in all of our experiments on day 7 for 24 h followed by 
assessment of Mn-related outcome measures. 
NPCs were split on day 6 of neuralization for these experiments: MTT survival assay, 
measurement of ROS, and assessment of mitochondrial fragmentation. Briefly, cells were 
washed once with DMEM-F12 (Invitrogen) and treated with 500 μl Accutase (Innovative Cell 
Technologies, San Diego, CA) per one well of a 12 well plate for 8–10 min at 37 °C. Another 
500 μl of neuralization medium was added to each well and the cells were thoroughly pipetted 
and transferred to a 15 ml conical tube and centrifuged (200 × g for 5 min). Cells were 
resuspended in 1 ml neuralization medium that contains 10 μM Rho-Kinase (ROCK) inhibitor, 
Y-27632 (Tocris), 10 μM SB431542 and 0.5 μM DMH1. NPCs were plated on Matrigel pre-
coated plates in this same medium in an assay-dependent cell density specified below. 
 
2.3. Cell viability assay 
Cell viability was assessed by splitting NPCs on day 6 of neural induction onto Matrigel-covered 
96 well plates at a density of 2 × 105 cell/ml. 500 or 1000 μM MnCl2 was added to the 
neuralization medium on day 7 of neuralization. After 24 h of exposure the neuralization 
medium was removed and the NPCs were washed once with PBS. Incubation with MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Research Organics) dye in 
neuralization medium followed for two and a half hours (Williams et al., 2010). The medium 
was subsequently removed, and cells were solubilized using 10% Sorenson's buffer in DMSO. 
Absorbance was read at 570 nM using a DTX 880 Multiplate Reader (Beckman Coulter). 
Absorbance was normalized to the vehicle-only exposed controls of each genotype for each 
independent experiment. Data were plotted using Prism5 (GraphPad) and analysis was 
performed using two-way ANOVA. The alpha level was set at p < 0.05. 
 
2.4. Quantification of Mn induced ROS production 
NPCs were split on day 6 of neuralization at a cell density of 2 × 105 cell/ml. On day 7 of 
neuralization, cells were washed twice with 100 μl KR-HEPES buffer. They were then incubated 
with 2 μM of the dichlorodihydrofluorescein-based dye CM-H2DCFDA (Invitrogen) in KR-
HEPES in the dark at 37 °C for 30 min. Cells were washed 3 times with 100 μl of KR-HEPES 
and the experimental conditions were added in KR-HEPES. Fluorescent measurements were 
taken using a Beckman Coulter DTX 880 microplate reader at 37 °C. The excitation wavelength 
was 485 nm (filter bandwidth ± 20 nm) and emission 535 nm (filter bandwidth ± 25 nm). 
Absorbance was normalized to the vehicle-only exposed controls of each genotype for each 
independent experiment. Two-way ANOVA was used for statistical analysis of log-transformed 
data; a Bonferroni test was used for post hoc analysis (Prism software). 
 
2.5. Mitochondrial fragmentation analysis 
NPCs were split on day 6 of neuralization and were re-plated on Matrigel coated 8 well glass 
slides (Thermo Scientific) with a density of 1 × 105 cells/ml. On day 7 of neuralization NPCs 
were exposed to either vehicle or 500 μM Mn. After 24 h of exposure NPCs were incubated with 
100 nM MitoTracker Red dye (Invitrogen) in neuralization medium for 45 min at 37 °C. The 
dye-containing medium was subsequently taken off and cells were incubated in dye-free 
neuralization medium for 10 min. Cells were washed once with PBS and fixed with 4% 
paraformaldehyde for 10–15 min at room temperature. Alternatively, the mitochondria-specific 
viral transduction system (CellLight Mitochondria-GFP, Backmam 2.0; Invitrogen) was used to 
label mitochondria. In this method, the reagent was added to NPCs on day 6 of neutralization 
during re-plating at a multiplicity of infection (MOI) of 20. NPCs were exposed after 24 h to 
either vehicle or Mn for another 24 h then fixed as specified above. Subsequently, NPCs were 
stained with PAX6 antibody (Neely et al., 2012), followed by nuclear counter staining using 2 
μM TO-PRO-3 dye (Invitrogen) for 10 min. The slides were cover-slipped with No. 1 cover slips 
using ProLong Gold mounting medium (Invitrogen). Confocal microscopy was used to assess 
mitochondrial morphology using a 63× objective lens. Analysis was done with blinding to the 
genotypes and exposure conditions. 50 PAX6+ cells per each condition were assessed for 
mitochondrial fragmentation (Lutz et al., 2009 and Sterky et al., 2011) in each experiment with 
cells chosen randomly from each of the four well quadrants. Apoptotic and mitotic cells were 
identified by morphology (shrunken cells with condensed nuclei and cells with fused nuclei, 
respectively) and excluded from the analysis. We developed a severity scale of four scores from 
1 to 4 to visually assess mitochondrial fragmentation. A score of one indicates that the cell has 
minimal mitochondrial fragmentation (<25%) with intact network formation, while a score of 4 
indicates severe mitochondrial fragmentation (>75%) with complete loss of mitochondrial 
tubular structure. Scores 2 and 3 indicate moderate mitochondrial fragmentation with some intact 
network structure, and moderate to severe fragmentation with only sparse mitochondrial tubular 
structure, respectively. The average mitochondrial fragmentation score of all assessed cells in an 
experimental condition reflects the overall severity of mitochondrial fragmentation. Statistical 
analysis was performed using two-way ANOVA on the log transformed average scores of all 
cells in each experiment using SPSS software, with a paired two-tailed t-test for post hoc 
analysis. 
 
2.6. Graphite furnace atomic absorption spectrometry (GFAAS) 
SM and CA NPCs differentiated on 12 well plates were treated with 500 μM MnCl2 on day 7 of 
neuralization for 24 h. Cells were washed once with PBS (1 ml/well). 250 μl of PBS was then 
added to each well. Cells were then scraped mechanically and flash frozen in liquid nitrogen then 
stored in −80 °C for two weeks. Total Mn level was analyzed in 3 independent vehicle-treated 
samples and 4 independent Mn-treated samples by GFAAS using a modified version of our 
published methods (Williams et al., 2010 and Yin et al., 2010). Bovine liver (NBS Standard 
Reference Material, USDC, Washington, DC) (10 μg Mn/g) was digested in ultrapure nitric acid 
and used as an internal standard for analysis (final concentration 10 μg Mn/L) as published 
previously (Anderson et al., 2009). Findings are reported as total Mn level (μg) normalized to 
total protein (mg). Data were analyzed by two-way ANOVA (Prism5 software, GraphPad) and 
the alpha level was set at p < 0.05. 
 
3. Results 
3.1. CA and SM NPCs exhibit identical sensitivity to acute Mn-induced cell death 
To test the hypothesis that NPCs from subjects CA and SM differ in their sensitivity to Mn 
cytotoxicity (i.e. cell death) we examined cell survival of day 7 NPCs following 24 h exposure to 
Mn. In a parallel study we determined the EC50 value for cell survival (by MTT assay) 
following 24-h Mn exposure using a concentration response curves (manuscript submitted). This 
analysis revealed an EC50 value of 1200 μM MnCl2 for cell death following Mn exposure. 
Furthermore, no significant differences were observed between CA and SM survival curves (data 
not shown). To increase statistical power for detection of subtle differences in sensitivity to Mn 
exposure we assessed cell viability of NPCs at 500 μM and 1000 μM MnCl2 using two 
independent control lines (CA6 and CA11) and three independent SM lines (SM3, SM5 and 
SM14) (Fig. 2). We did not detect a significant difference in Mn cytotoxicity between SM and 
CA NPCs. Thus SM and CA NPCs display statistically identical sensitivities to acute Mn-
induced cell death. 
 
Fig. 2. Mn cytotoxicity in NPCs. CA and SM NPCs were treated with Mn and cell viability was 
assessed using MTT assay. Two-way ANOVA revealed significant exposure effect (p < 0.001) 
without a significant genotype effect (p = 0.345). CA lines used in this experiment include CA6 
(n = 2) and CA11 (n = 2), and SM lines include SM3 (n = 1), SM5 (n = 1), and SM14 (n = 1). 
Data are collected from 3 independent replicates. Error bars represent SEM. 
3.2. CA and SM NPCs generate elevated Mn-dependent reactive oxygen species (ROS) 
Although no differences in sensitivity to Mn cytotoxicity were found, we tested the hypothesis 
that SM NPCs may be more prone to ROS generation after Mn exposure. Mn neurotoxicity has 
been linked to the enhanced generation of ROS (Gunter et al., 2004 and Tamm et al., 2008). 
Moreover, Parkin (protein product of the PARK2 gene) has been implicated in maintenance of 
mitochondrial turnover and loss of this function might predispose cells to generate higher ROS 
(Koh and Chung, 2010). We tested the levels of ROS in CA and SM NPCs by using the ROS-
sensitive dye 2′,7′-dichlorofluorescein (DCF) following Mn exposure. We found that SM NPCs 
generated increased DCF detected ROS relative to CA NPCs after 30 min MnCl2 exposure (Fig. 
3). Two-way ANOVA of both low and high Mn exposure levels identified a significant genotype 
effect (p = 0.001). Bonferroni post hoc analysis showed a significant difference between SM and 
CA at both 500 μM (p < 0.05) and 1000 μM (p < 0.01) Mn exposures. 
 
Fig. 3. ROS generation in NPCs. NPCs are treated with two concentrations of manganese and the 
level of ROS generation was assessed using DCF dye. Two-way ANOVA on the log-
transformed values returned genotype difference (p = 0.001) but no genotype × exposure 
interaction. CA lines used in these experiments include CA6 (n = 2–3) and CA11 (n = 2–3); and 
SM lines include SM3 (n = 2–3) and SM14 (n = 2–3). Data are collected from four independent 
500 μM and six independent 1000 μM MnCl2 experiments. Error bars represent SEM. 
3.3. Increase in Mn-dependent mitochondrial fragmentation is similar between CA and SM 
Loss of PARK2 function has been associated with increased mitochondrial fragmentation ( 
Greene et al., 2003 and Lutz et al., 2009). We hypothesized that Mn exposure, which is known to 
cause mitochondrial dysfunction ( Brown and Taylor, 1999 and Malecki, 2001), would cause 
more mitochondrial fragmentation in SM NPCs than CA. We found that Mn exposure was 
associated with increased mitochondrial fragmentation, as assessed using MitoTracker Red dye, 
in both CA and SM NPCs (Fig. 4). Two-way ANOVA of the average mitochondrial 
fragmentation score revealed a highly significant Mn exposure effect (p = 0.008) with no 
significant differences by genotype (p = 0.44) nor the two-way interaction term (p = 0.269). 
 
Fig. 4. Quantification of mitochondrial fragmentation in NPCs using MitoTracker Red. CA and 
SM NPCs are treated with 500 μM MnCl2 for 24 h followed by mitochondrial staining using 
MitoTracker Red dye (100 nM). 50 PAX6+ cells were counted for each condition and scored 
from 1 to 4 increasing with severity of mitochondrial fragmentation. The average score of cells 
assessed for three independent experiments after exposure to 0 or 500 μM Mn. Two-way 
ANOVA on the log-transformed data returned high significance for the effect of Mn exposure, 
but no genotype or genotype × exposure interaction effects. Paired two-tailed t-test was used for 
post hoc analysis of the three independent paired experiments: CA6 with SM4 (n = 1), and CA6 
with SM5 (n = 2). Error bars represent SEM. 
In an independent set of experiments, we used the CellLight Mitochondria-GFP transduction 
system as an alternative approach to assess mitochondrial morphology. This mitochondria 
labeling system utilizes Baculovirus particles to deliver a GFP fusion protein with the leader 
sequence of the E1 alpha pyruvate dehydrogenase that is specific to mitochondria. Unlike 
MitoTracker Red dye, CellLight reagent does not rely on membrane potential for mitochondrial 
localization. This property makes CellLight a control for the possible influence of decreased 
membrane potential due to Mn exposure on our assessment of mitochondrial morphology by 
MitoTracker Red. We found that, compared to vehicle-exposed NPCs, Mn exposure was 
associated with increased mitochondrial fragmentation and disruption of the mitochondrial 
tubular structure (Fig. 5). Two-way ANOVA of mean mitochondrial fragmentation scores 
performed on this independent set of experiments also revealed a significant Mn exposure effect 
(p = 0.0019), with no significant differences by genotype (p = 0.556) or the two-way interaction 
term (p = 0.956). Thus both methods of mitochondrial labeling revealed comparable influence of 
Mn on mitochondrial fragmentation with no significant effect of genotype. 
 
Fig. 5. Quantification of mitochondrial fragmentation in NPCs using CellLight Mitochondria-
GFP. Representative images are shown for CA and SM vehicle- and Mn-treated NPCs after 
staining with CellLight Mitochondria-GFP and TO-PRO-3 nuclear counterstain. PAX6+ NPCs 
were analyzed for mitochondrial fragmentation as described in Section 2.5. (CA6: SM3 n = 2, 
CA11:SM14 n = 1). Scale bar = 10 μm. 
3.4. Decreased net Mn uptake in SM NPCs versus CA 
The data above indicated enhanced ROS generation in SM NPCs compared to CA after Mn 
exposure despite similar effects on cell survival and mitochondrial morphology. Thus we tested 
the hypothesis that SM NPCs may accumulate increased levels of intracellular Mn following 
exposure. This is especially relevant given the evidence for Parkin involvement in manganese 
transport through degradation of DMT1 (Roth et al., 2010). Remarkably, we found that SM 
NPCs accumulated about 35% less intracellular Mn than CA NPCs after Mn exposure (Fig. 6). 
Two-way ANOVA revealed a highly significant main effect of genotype (p = 0.009), exposure (p 
< 0.001), and genotype × exposure interaction (p = 0.014). 
 
Fig. 6. Measurement of total Mn accumulation in SM and CA NPCs using (GFAAS). 
Intracellular Mn accumulation was assessed in CA and SM NPCs after exposure to vehicle and 
500 μM Mn. Outputs were normalized to the protein concentration of each sample. Two-way 
ANOVA revealed significant genotype difference in total Mn level after Mn exposure (p = 009). 
CA6 and SM5 lines were used in these experiments. Data are collected from 3 independent 
vehicle exposed samples and 4 independent Mn treated samples. Error bars represent SEM. 
4. Discussion 
We report here a proof-of-principle study to evaluate the potential of patient stem cell derived 
neuronal models to predict the contribution of individual genetic variability to Mn neurotoxicity 
by examining early neural progenitors of two human subjects with disparate genetic risk factors 
for PD. We present a case of a subject (SM) having a family history (an affected sibling) as well 
as inheritance of a known PD genetic risk factor (compound heterozygous mutations in PARK2) 
versus another subject (CA) with no know PD genetic risk factors or family history of PD. We 
focused on outcome measures functionally linked to PARK2 gene function and Mn toxicity such 
as regulation of mitochondrial biogenesis and turnover ( Koh and Chung, 2010, Lutz et al., 2009 
and Yin et al., 2008) and Mn transport (Roth et al., 2010). We found that exposure of human 
NPCs to Mn resulted in cell death, increased ROS generation, and mitochondrial fragmentation. 
ROS generation was significantly higher in SM-derived NPCs compared to CA-derived NPCs. 
This suggests enhanced sensitivity of SM NPCs to Mn exposure, especially considering the 
significantly lower Mn accumulation in SM NPCs compared to CA after Mn exposure. Thus, the 
near equivalent cytotoxicity and mitochondrial fragmentation in CA and SM NPCs occurs in the 
face of significantly less intracellular Mn in the SM-derived cells. We propose that the enhanced 
susceptibility of SM NPCs to the deleterious effects of Mn is due to differences in susceptibility 
to intracellular Mn despite equivalent cellular accumulation of the metal. This could be due to 
failure of one or more cellular mechanisms that are normally involved in maintaining normal 
homeostasis during stress, such as oxidative stress response mechanisms and mitochondrial 
biogenesis rates. Furthermore, the decreased net uptake of Mn in the SM NPCs suggests the 
possibility of the activation of compensatory mechanisms to limit Mn toxicity in the face of 
heightened sensitivity. Together, our data strongly indicate that NPCs from a human subject with 
strong PD genetic risk factors have elevated sensitivity to Mn neurotoxicity compared to a 
subject without these risk factors. 
 
Mn concentrations used in this study are slightly higher (about 2- to 3-fold) than typically seen in 
vivo following pathophysiological Mn exposure. Normally, brain Mn levels average around 1–2 
μg/g (18–36 μM) with the highest level being in the globus pallidus in human and hypothalamus 
in rats ( Bowman et al., 2011 and Prohaska, 1987). Studies in rodents indicate that these 
concentration increase by a magnitude of approximately 2- to 10-fold after acute Mn exposure 
(Madison et al., 2012). Concentrations as high as 500 μM fail to produce significant cytotoxicity 
over the exposure durations (up to 48 h) in NPCs. This is consistent with in vivo data wherein 
acute exposure to Mn, during which brain Mn levels likely do not exceed ∼400 μM, is not 
associated with substantial neurodegeneration (Madison et al., 2012). Moreover, other groups 
have reported similar sensitivities of culture human cells to Mn ( Roth et al., 2000 and Roth et 
al., 2012). One reasonable explanation for the apparent resistance of cells to high concentrations 
of Mn in tissue culture media could be the binding of Mn to serum proteins and other 
constituents of media that decrease the availability of free Mn. 
 
Although a previous study showed that Parkin promotes degradation of the 1B isoform of DMT1 
and lowers Mn levels consequently (Roth et al., 2010), the influence of long-term loss of human 
PARK2 expression in the context of neural lineages has not been examined. One possible 
hypothesis to explain the differential accumulation of Mn is a potential discrepancy is cellular 
compensation of SM cells in response to a heighten sensitivity to Mn toxicity. One mechanism 
by which this may occur would be to increase efflux of Mn via metal exporters such as 
ferroportin (Yin et al., 2010). Another intriguing possibility could be human genetic variation 
outside of the PARK2 mutation that influences cellular Mn status. 
 
The finding of mitochondrial dysfunction in human NPCs after Mn exposure is not surprising 
given the previously reported observation of mitochondrial toxicity in other model systems 
(Malecki, 2001 and Zhang et al., 2008). The assessment of Mn-related ROS generation and 
mitochondrial dysfunction in human-derived neurons is an important advancement, however, as 
it has the potential to answer important questions about the subject-specific susceptibility to Mn 
and other compounds. 
 
In conclusion, we show here a strong proof-of-principle support for the modeling of subject-
specific human Mn neurotoxicity using iPS model system. We have demonstrated that, in this 
example, a human subject with a family history of PD and inheritance of a strong genetic risk 
factor for PD exhibited elevated susceptibility to disease relevant Mn toxicity than iPS-derived 
NPCs from a control subject. Our findings appear to suggest a potentially protective cellular 
response to decrease Mn accumulation upon exposure and thereby attenuate Mn-dependent 
phenotypes. Further studies should be carried out to understand whether the decreased Mn 
accumulation is functionally linked to the PARK2 mutation or other genetic factors. Future 
experiments might also reveal a different sensitivity profile of neurons as they are differentiated 
further down the nigral dopaminergic lineage toward the vulnerable neuronal population in PD. 
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